Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Core Points - Lyra Therapeutics, Inc. has announced a definitive agreement for a registered direct offering of 423,372 shares of common stock and concurrent private placement of warrants to purchase up to 846,744 shares of common stock, with a combined effective purchase price of $11.81 per share [1][3] - The gross proceeds from the offering are expected to be approximately $5.0 million, with potential additional proceeds of approximately $9.8 million if the private placement warrants are fully exercised [3][4] - The company intends to use the net proceeds for working capital and other general corporate purposes, including clinical development and pre-commercialization expenses for LYR-210 [3] Offering Details - The offering is expected to close on or about June 27, 2025, subject to customary closing conditions [3] - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2] - The securities offered in the registered direct offering are being made pursuant to a shelf registration statement previously filed with the SEC [5] Private Placement Warrants - The private placement warrants have an exercise price of $11.56 per share and will expire twenty-four months after the effective date of the resale registration statement [1] - The private placement warrants were offered in a private placement under Section 4(a)(2) of the Securities Act and have not been registered under the Act [6]